

Pierre B Zachar[©]e

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3484851/publications.pdf>

Version: 2024-02-01

70
papers

4,140
citations

126907

33
h-index

114465

63
g-index

70
all docs

70
docs citations

70
times ranked

4719
citing authors

#	ARTICLE	IF	CITATIONS
1	Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera. <i>New England Journal of Medicine</i> , 2015, 372, 426-435.	27.0	720
2	Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. <i>Blood</i> , 2009, 113, 5401-5411.	1.4	540
3	Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. <i>Lancet Haematology</i> , 2017, 4, e317-e324.	4.6	243
4	No Evidence for the Benefit of Gonadotropin-Releasing Hormone Agonist in Preserving Ovarian Function and Fertility in Lymphoma Survivors Treated With Chemotherapy: Final Long-Term Report of a Prospective Randomized Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 2568-2574.	1.6	199
5	Antifungal Prophylaxis with Itraconazole in Prolonged Neutropenia: Correlation with Plasma Levels. <i>Mycoses</i> , 1989, 32, 103-108.	4.0	173
6	Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison. <i>Blood</i> , 2009, 113, 1375-1382.	1.4	158
7	Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy. <i>Journal of Clinical Oncology</i> , 2017, 35, 1905-1912.	1.6	143
8	Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 2575-2582.	1.6	142
9	Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial. <i>Haematologica</i> , 2016, 101, 821-829.	3.5	140
10	Gonadotropin-Releasing Hormone Agonist for the Prevention of Chemotherapy-Induced Ovarian Failure in Patients With Lymphoma: 1-Year Follow-Up of a Prospective Randomized Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 903-909.	1.6	108
11	Randomized, Double-Blind, Active-Controlled Trial of Every-3-Week Darbepoetin Alfa for the Treatment of Chemotherapy-Induced Anemia. <i>Journal of the National Cancer Institute</i> , 2006, 98, 273-284.	6.3	97
12	Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study. <i>Lancet Haematology</i> , 2020, 7, e226-e237.	4.6	93
13	The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF). <i>British Journal of Haematology</i> , 2017, 176, 76-85.	2.5	69
14	Phase I/II Clinical Study of Tosedostat, an Inhibitor of Aminopeptidases, in Patients With Acute Myeloid Leukemia and Myelodysplasia. <i>Journal of Clinical Oncology</i> , 2010, 28, 4333-4338.	1.6	67
15	AIDS AND CRYPTOCOCCOSIS (ZAIRE, 1977). <i>Lancet</i> , 1983, 321, 925-926.	13.7	65
16	Allogeneic and syngeneic hematopoietic cell transplantation in patients with amyloid light-chain amyloidosis: a report from the European Group for Blood and Marrow Transplantation. <i>Blood</i> , 2006, 107, 2578-2584.	1.4	62
17	Further evidence for the clonal nature of the idiopathic hypereosinophilic syndrome: complete haematological and cytogenetic remission induced by interferon-alpha in a case with a unique chromosomal abnormality. <i>British Journal of Haematology</i> , 1996, 92, 176-183.	2.5	59
18	Myelodysplastic syndromes with bone marrow fibrosis: a myelodysplastic disorder with proliferative features. <i>Annals of Hematology</i> , 1991, 63, 235-241.	1.8	56

#	ARTICLE	IF	CITATIONS
19	Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2017, 52, 372-380.	2.4	53
20	Recombinant human erythropoietin for the treatment of anemia in the myelodysplastic syndromes: A clinical and erythrokinetic assessment. <i>Annals of Hematology</i> , 1992, 64, 16-21.	1.8	50
21	Allogeneic Stem Cell Transplantation for Patients Age \geq 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 44-52.	2.0	49
22	Hematologic aspects of end-stage renal failure. <i>Annals of Hematology</i> , 1994, 69, 33-40.	1.8	48
23	Risks of rhG-CSF treatment in drug-induced agranulocytosis. <i>Annals of Hematology</i> , 1995, 70, 143-147.	1.8	46
24	Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy. <i>European Journal of Haematology</i> , 2016, 97, 192-200.	2.2	46
25	CYCLOSPORIN, METHYLPREDNISOLONE, AND CONVULSIONS. <i>Lancet</i> , The, 1982, 320, 1216-1217.	13.7	45
26	Translocation t(6;9) occurring in acute myelofibrosis, myelodysplastic syndrome, and acute nonlymphocytic leukemia suggests multipotent stem cell involvement. <i>Cancer Genetics and Cytogenetics</i> , 1989, 42, 209-219.	1.0	43
27	Erythropoietin Resistance due to Vitamin B ₁₂ Deficiency. <i>American Journal of Nephrology</i> , 1992, 12, 188-191.	3.1	42
28	Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II study. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 581-591.	2.3	42
29	Imaging red blood cells with the atomic force microscope. <i>British Journal of Haematology</i> , 1996, 95, 472-481.	2.5	38
30	Patients with high-risk myelodysplastic syndrome can have polyclonal or clonal haemopoiesis in complete haematological remission. <i>British Journal of Haematology</i> , 1998, 102, 486-494.	2.5	38
31	Pseudo-Pulmonary Embolism as a Sign of Acute Heparin-Induced Thrombocytopenia in Hemodialysis Patients: Safety of Resuming Heparin after Disappearance of HIT Antibodies. <i>Nephron Clinical Practice</i> , 2006, 104, c143-c148.	2.3	37
32	Non-myeloablative allogeneic hematopoietic cell transplantation following fludarabine plus 2Â Gy TBI or ATG plus 8Â Gy TLI: a phase II randomized study from the Belgian Hematological Society. <i>Journal of Hematology and Oncology</i> , 2015, 8, 4.	17.0	37
33	Granulocyte colony-stimulating factor-induced capillary leak syndrome confirmed by extravascular lung water measurements. <i>Annals of Hematology</i> , 2005, 84, 89-94.	1.8	34
34	A phase I first-in-human study with tefinostat â€“ a monocyte/macrophage targeted histone deacetylase inhibitor â€“ in patients with advanced haematological malignancies. <i>British Journal of Haematology</i> , 2013, 162, 191-201.	2.5	32
35	Comparative study of peripheral blood progenitor cell collection in patients with multiple myeloma after single-dose cyclophosphamide combined with rhGM-CSF or rhG-CSF. <i>British Journal of Haematology</i> , 1995, 90, 384-392.	2.5	31
36	Long-term survival data from a phase 3 study of Filgrastim as an adjunct to chemotherapy in adults with de novo acute myeloid leukemia. <i>Leukemia</i> , 2006, 20, 404-409.	7.2	28

#	ARTICLE	IF	CITATIONS
37	Psoralen and Ultraviolet A Light Treatment Directly Affects Phosphatidylinositol 3-Kinase Signal Transduction by Altering Plasma Membrane Packing. <i>Journal of Biological Chemistry</i> , 2016, 291, 24364-24376.	3.4	26
38	Imaging Uremic Red Blood Cells with the Atomic Force Microscope. <i>American Journal of Nephrology</i> , 1994, 14, 197-200.	3.1	25
39	Controversies in Selection of Epoetin Dosages. <i>Drugs</i> , 1995, 49, 536-547.	10.9	24
40	Plasma Exchange--Associated Immunoglobulin M--Negative Hantavirus Disease after a Camping Holiday in Southern France. <i>Clinical Infectious Diseases</i> , 2004, 38, 1350-1356.	5.8	24
41	Thallium Intoxication Treated with Combined Hemoperfusion-Hemodialysis. <i>Journal of Toxicology: Clinical Toxicology</i> , 1982, 19, 259-264.	1.5	22
42	Hypercalcemia, monoclonal protein, and osteolytic bone lesions in chronic lymphocytic leukemia. <i>Annals of Hematology</i> , 1994, 69, 79-80.	1.8	16
43	Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 4144-4154.	3.3	16
44	A male with angioimmunoblastic T-cell lymphoma and proliferative glomerulonephritis. <i>Annals of Hematology</i> , 2004, 83, 455-459.	1.8	14
45	<i>Massilia timonae</i> Infection Presenting as Generalized Lymphadenopathy in a Man Returning to Belgium from Nigeria. <i>Journal of Clinical Microbiology</i> , 2011, 49, 2763-2765.	3.9	12
46	Parvovirus infection causing red cell aplasia and leukopenia in rheumatoid arthritis. <i>Clinical Rheumatology</i> , 1994, 13, 129-131.	2.2	11
47	An update on peripheral blood progenitor cell transplantation. <i>Annals of Hematology</i> , 1995, 71, 29-33.	1.8	11
48	Acute myeloid leukemia with bone marrow necrosis and Charcot Leyden crystals. <i>American Journal of Hematology</i> , 2007, 82, 1029-1029.	4.1	10
49	Atypical myeloproliferative disorders in adults. <i>Transfusion and Apheresis Science</i> , 2011, 44, 211-221.	1.0	7
50	Myelofibrosis patients in Belgium: disease characteristics. <i>Acta Clinica Belgica</i> , 2015, 70, 105-111.	1.2	7
51	PYRUVATE KINASE DEFICIENCY AND DELAYED CLINICAL RESPONSE TO RECOMBINANT HUMAN ERYTHROPOIETIN TREATMENT. <i>Lancet, The</i> , 1989, 333, 1327-1328.	13.7	6
52	Safety of Combining Ticlopidine with Nadroparin in the Routine Treatment of Chronic Hemodialysis Patients. <i>Nephron</i> , 1997, 77, 484-485.	0.6	6
53	Interruption or Discontinuation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukaemia: A Retrospective Cohort Study (SPARKLE) in Belgium. <i>Acta Haematologica</i> , 2019, 142, 197-207.	1.4	6
54	Therapy-related acute myeloid leukemia with t(8;16)(p11;p13) following anthracycline-based therapy for nonmetastatic osteosarcoma. <i>Cancer Genetics and Cytogenetics</i> , 1995, 82, 103-105.	1.0	5

#	ARTICLE	IF	CITATIONS
55	Disease and treatment characteristics of polycythemia vera patients in Belgium: Results from a scientific survey. <i>European Journal of Haematology</i> , 2018, 100, 361-366.	2.2	5
56	Comprehensive haematological control with ruxolitinib in patients with polycythaemia vera resistant to or intolerant of hydroxycarbamide. <i>British Journal of Haematology</i> , 2018, 182, 279-284.	2.5	3
57	Red Blood Cells, the Scavengers for Toxic Free Radicals During Haemodialysis. <i>Nephrology Dialysis Transplantation</i> , 1988, , .	0.7	2
58	Erythropoietin, aluminium, and anaemia in patients on haemodialysis. <i>Lancet</i> , The, 1990, 335, 1038-1039.	13.7	2
59	MRI findings in renal cortical hemosiderosis. <i>European Journal of Radiology</i> , 1992, 15, 239-241.	2.6	2
60	Recommendations on the use of ruxolitinib for the treatment of myelofibrosis. <i>Hematology</i> , 2018, 23, 194-200.	1.5	2
61	Reply to Z. Blumenfeld et al. <i>Journal of Clinical Oncology</i> , 2013, 31, 3722-3723.	1.6	1
62	Plerixafor prescription modalities in autologous haematopoietic stem cell mobilization in Belgium. <i>Acta Clinica Belgica</i> , 2015, 70, 16-22.	1.2	1
63	Reply to M. Lambertini et al. <i>Journal of Clinical Oncology</i> , 2017, 35, 805-806.	1.6	1
64	CONSTITUTION AND BEHAVIOUR OF THE SPHEROCYTE MEMBRANE. <i>British Journal of Haematology</i> , 1992, 81, 625-625.	2.5	0
65	Rccombinant human erythropoietin dosage requirements over the years. <i>Nephrology Dialysis Transplantation</i> , 0, , .	0.7	0
66	Transplantatie met gezuiverde stamcellen bij patiënten met gemetastaseerde tumoren. <i>Tijdschrift Voor Geneeskunde</i> , 1998, 54, 332-337.	0.0	0
67	Primaire amyloïdose. <i>Tijdschrift Voor Geneeskunde</i> , 1998, 54, 338-344.	0.0	0
68	Polycythaemia rubra vera: evoluties in diagnose en therapie. <i>Tijdschrift Voor Geneeskunde</i> , 1999, 55, 1154-1159.	0.0	0
69	Bloed- en beenmergtransplantatie voor ernstige auto-immune aandoeningen. <i>Tijdschrift Voor Geneeskunde</i> , 1999, 55, 1160-1165.	0.0	0
70	Zin en onzin van de deleukocyttering van bloedproducten. <i>Tijdschrift Voor Geneeskunde</i> , 1999, 55, 1166-1169.	0.0	0